Biggest changeDiluted earnings per share reconciliation to adjusted earnings per share (shares in thousands): Year Ended June 30, 2024 2023 Diluted earnings per share (GAAP) $ 3.39 $ 2.05 Effect on diluted earnings per share: Restructuring expense 0.05 0.41 Business acquisition and integration expense 0.85 0.94 Amortization of acquired intangible assets 0.88 1.34 Gain on sale of assets - (0.29) Write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, loss on assets held for sale, and debt modification costs 0.52 0.42 Tax benefit due to change in valuation allowance - (0.14) Tax benefit due to change in unrecognized tax benefits (0.14) - Income tax impact on non-GAAP adjustments (1) (0.57) (0.70) Loss from discontinued operations 0.02 0.18 Adjusted earnings per share (non-GAAP) $ 5.01 $ 4.21 Diluted shares used in non-GAAP EPS calculation 40,307 45,600 (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. 51 Table of Contents Reconciliation to adjusted EBITDA (in thousands): Year Ended June 30, Increase/(Decrease) 2024 2023 $ % Chamberlain: Operating income (GAAP) $ 137,800 $ 134,685 $ 3,115 2.3 % Restructuring expense — 818 (818) Depreciation 18,752 17,175 1,577 Amortization of cloud computing implementation assets 1,332 89 1,243 Stock-based compensation 8,303 4,719 3,584 Adjusted EBITDA (non-GAAP) $ 166,187 $ 157,486 $ 8,701 5.5 % Adjusted EBITDA margin (non-GAAP) 26.2 % 27.6 % Walden: Operating income (GAAP) $ 77,179 $ 35,880 $ 41,299 115.1 % Restructuring expense (776) 3,245 (4,021) Amortization of acquired intangible assets 35,644 61,239 (25,595) Litigation reserve 18,500 10,000 8,500 Depreciation 7,389 9,419 (2,030) Amortization of cloud computing implementation assets 1,331 73 1,258 Stock-based compensation 7,525 3,861 3,664 Adjusted EBITDA (non-GAAP) $ 146,792 $ 123,717 $ 23,075 18.7 % Adjusted EBITDA margin (non-GAAP) 24.7 % 23.2 % Medical and Veterinary: Operating income (GAAP) $ 71,065 $ 59,649 $ 11,416 19.1 % Restructuring expense 442 7,687 (7,245) Depreciation 11,983 12,438 (455) Amortization of cloud computing implementation assets 469 37 432 Stock-based compensation 4,930 3,003 1,927 Adjusted EBITDA (non-GAAP) $ 88,889 $ 82,814 $ 6,075 7.3 % Adjusted EBITDA margin (non-GAAP) 25.0 % 23.9 % Home Office: Operating loss (GAAP) $ (68,990) $ (62,044) $ (6,946) (11.2) % Restructuring expense 2,204 7,067 (4,863) Business acquisition and integration expense 34,215 42,661 (8,446) Loss on assets held for sale 647 — 647 Debt modification costs 848 — 848 Gain on sale of assets — (13,317) 13,317 Depreciation 1,552 2,344 (792) Stock-based compensation 5,189 2,716 2,473 Adjusted EBITDA (non-GAAP) $ (24,335) $ (20,573) $ (3,762) (18.3) % Adtalem Global Education: Net income (GAAP) $ 136,777 $ 93,358 $ 43,419 46.5 % Loss from discontinued operations 936 8,394 (7,458) Interest expense 63,659 63,100 559 Other income, net (10,542) (6,965) (3,577) Provision for income taxes 26,224 10,283 15,941 Operating income (GAAP) 217,054 168,170 48,884 Depreciation and amortization 78,452 102,814 (24,362) Stock-based compensation 25,947 14,299 11,648 Restructuring expense 1,870 18,817 (16,947) Business acquisition and integration expense 34,215 42,661 (8,446) Litigation reserve 18,500 10,000 8,500 Loss on assets held for sale 647 — 647 Debt modification costs 848 — 848 Gain on sale of assets — (13,317) 13,317 Adjusted EBITDA (non-GAAP) $ 377,533 $ 343,444 $ 34,089 9.9 % Adjusted EBITDA margin (non-GAAP) 23.8 % 23.7 % 52 Table of Contents
Biggest changeDiluted earnings per share reconciliation to adjusted earnings per share (shares in thousands): Year Ended June 30, 2025 2024 Diluted earnings per share (GAAP) $ 6.18 $ 3.39 Effect on diluted earnings per share: Restructuring expense 0.09 0.05 Business integration expense - 0.85 Amortization of acquired intangible assets 0.29 0.88 Write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs 0.10 0.52 Strategic advisory costs 0.31 - Tax benefit due to change in unrecognized tax benefits - (0.14) Income tax impact on non-GAAP adjustments (1) (0.19) (0.57) (Income) loss from discontinued operations (0.11) 0.02 Adjusted earnings per share (non-GAAP) $ 6.67 $ 5.01 Diluted shares used in non-GAAP EPS calculation 38,334 40,307 (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. 49 Table of Contents Reconciliation to adjusted EBITDA (in thousands): Year Ended June 30, Increase/(Decrease) 2025 2024 $ % Chamberlain: Adjusted operating income (GAAP) $ 153,367 $ 137,800 $ 15,567 11.3 % Depreciation 21,687 18,752 2,935 Amortization of cloud computing implementation assets 3,033 1,332 1,701 Stock-based compensation 13,309 8,303 5,006 Adjusted EBITDA (non-GAAP) $ 191,396 $ 166,187 $ 25,209 15.2 % Adjusted EBITDA margin (non-GAAP) 26.4 % 26.2 % Walden: Adjusted operating income (GAAP) $ 183,581 $ 130,547 $ 53,034 40.6 % Depreciation 7,421 7,389 32 Amortization of cloud computing implementation assets 3,002 1,331 1,671 Stock-based compensation 12,477 7,525 4,952 Adjusted EBITDA (non-GAAP) $ 206,481 $ 146,792 $ 59,689 40.7 % Adjusted EBITDA margin (non-GAAP) 29.8 % 24.7 % Medical and Veterinary: Adjusted operating income (GAAP) $ 69,252 $ 71,507 $ (2,255) (3.2) % Depreciation 10,853 11,983 (1,130) Amortization of cloud computing implementation assets 1,208 469 739 Stock-based compensation 7,486 4,930 2,556 Adjusted EBITDA (non-GAAP) $ 88,799 $ 88,889 $ (90) (0.1) % Adjusted EBITDA margin (non-GAAP) 24.1 % 25.0 % Home Office: Adjusted operating loss $ (36,030) $ (31,076) $ (4,954) (15.9) % Depreciation 741 1,552 (811) Stock-based compensation 8,318 5,189 3,129 Adjusted EBITDA $ (26,971) $ (24,335) $ (2,636) (10.8) % Adtalem Global Education: Net income (GAAP) $ 237,065 $ 136,777 $ 100,288 73.3 % (Income) loss from discontinued operations (4,388) 936 (5,324) Interest expense 52,318 63,659 (11,341) Other income, net (9,290) (10,542) 1,252 Provision for income taxes 65,837 26,224 39,613 Depreciation and amortization 59,165 78,452 (19,287) Stock-based compensation 41,590 25,947 15,643 Restructuring expense 3,314 1,870 1,444 Business integration expense — 34,215 (34,215) Litigation reserve (5,550) 18,500 (24,050) Asset impairments 6,442 — 6,442 Strategic advisory costs 12,000 — 12,000 Loss on assets held for sale 490 647 (157) Debt modification costs 712 848 (136) Adjusted EBITDA (non-GAAP) $ 459,705 $ 377,533 $ 82,172 21.8 % Adjusted EBITDA margin (non-GAAP) 25.7 % 23.8 %
The decrease in the percentage was primarily the resul t of revenue growth accompanied with cost efficiencies. Student Services and Administrative Expense The student services and administrative expense category includes expenses related to student admissions, marketing and advertising, general and administrative, and amortization expense of acquired intangible assets.
The decrease in the percentage was primarily the resul t of revenue growth accompanied with cost efficiencies. Student Services and Administrative Expense The student services and administrative expense category includes expenses related to student admissions, marketing and advertising, general and administrative, and amortization of acquired intangible assets.
Medical and Veterinary – Offers degree and certificate programs in the medical and veterinary postsecondary education industry. This segment includes the operations of AUC, RUSM, and RUSVM, which are collectively referred to as the “medical and veterinary schools.” “Home Office” includes activities not allocated to a reportable segment.
Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry. “Home Office” includes activities not allocated to a reportable segment.
We do not include normal, recurring, cash operating expenses in our restructuring expense. ● Business acquisition and integration expense include expenses related to the Walden acquisition and certain costs related to growth transformation initiatives.
We do not include normal, recurring, cash operating expenses in our restructuring expense. ● Business integration expense includes expenses related to the Walden acquisition and certain costs related to growth transformation initiatives.
“Financial Statements and Supplementary Data.” 49 Table of Contents Non-GAAP Financial Measures and Reconciliations We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Adtalem’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons.
“Financial Statements and Supplementary Data.” 47 Table of Contents Non-GAAP Financial Measures and Reconciliations We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Adtalem’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons.
See the “Non-GAAP Financial Measures and Reconciliations” 36 Table of Contents section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures. Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands.
See the “Non-GAAP Financial Measures and Reconciliations” 35 Table of Contents section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures. Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands.
Discussions throughout this MD&A are based on continuing operations unless otherwise noted. The MD&A should be read in conjunction with the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” and the notes thereto. The following discussion is on the comparison between fiscal year 2024 and fiscal year 2023 results.
Discussions throughout this MD&A are based on continuing operations unless otherwise noted. The MD&A should be read in conjunction with the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” and the notes thereto. The following discussion is on the comparison between fiscal year 2025 and fiscal year 2024 results.
(Provision for) Benefit from Income Taxes Our effective income tax rate (“ETR”) from continuing operations can differ from the 21% U.S. federal statutory rate due to several factors, including tax on global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, liabilities for uncertain tax positions, and tax benefits on stock-based compensation awards.
Provision for Income Taxes Our effective income tax rate from continuing operations can differ from the 21% U.S. federal statutory rate due to several factors, including tax on global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation awards.
If the carrying value of the indefinite-lived intangible assets exceeds its fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value. For intangible assets with finite lives, we evaluate for potential impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
If the carrying value of the indefinite-lived intangible assets exceeds their fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value. For intangible assets with finite lives, we evaluate for potential impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
Goodwill and Intangible Assets Goodwill and indefinite-lived intangible assets are not amortized, but are tested for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31.
Goodwill and Intangible Assets Goodwill and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31.
Significant judgement is involved in determining whether a triggering event has occurred, and significant assumptions are used in the estimation of future cash flows and fair values of long-lived assets. Changes in our judgments and assumptions could result in impairments of long-lived assets in future periods.
Significant judgment is involved in determining whether a triggering event has occurred, and significant assumptions are used in the estimation of future cash flows and fair values of long-lived assets. Changes in our judgments and assumptions could result in impairments of long-lived assets in future periods.
Management’s focus is on increasing enrollment and renewing operational effectiveness, specifically around academic support, the enrollment experience, and marketing.
Management’s focus is on increasing enrollment and renewing operational effectiveness, specifically around academic support and the enrollment experience.
The valuation of liabilities for these contingencies is reviewed on a quarterly basis and any necessary adjustments to the accrual on the Consolidated Balance Sheets is recorded. While we believe that the amount accrued to-date is adequate, future changes in circumstances could impact these determinations. See Note 21 “Commitments and Contingencies” to the Consolidated Financial Statements in Item 8.
The valuation of liabilities for these contingencies is reviewed on a quarterly basis and any necessary adjustments to the accrual on the Consolidated Balance Sheets are recorded. While we believe that the amount accrued to-date is adequate, future changes in circumstances could impact these determinations. See Note 18 “Commitments and Contingencies” to the Consolidated Financial Statements in Item 8.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report.
For a discussion on the comparison between fiscal year 2023 and fiscal year 2022 results, see the MD&A included in Adtalem’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, as filed with the SEC.
For a discussion on the comparison between fiscal year 2024 and fiscal year 2023 results, see the MD&A included in Adtalem’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024, as filed with the SEC.
“Financial Statements and Supplementary Data” for additional information on our loss contingencies. Recent Accounting Pronouncements For a discussion of recent accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements in Item 8.
“Financial Statements and Supplementary Data” for additional information on our loss contingencies. Recent Accounting Pronouncements For information regarding recent accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements in Item 8.
Such assessments involve significant judgements and are subject to change in the future particularly if earnings are significantly different from expectations.
Such assessments involve significant judgments and are subject to change in the future particularly if earnings are significantly different from expectations.
If economic conditions deteriorate, interest rates rise, or operating performance of our reporting units do not meet expectations such that we revise our long-term forecasts, we may recognize impairments of goodwill and other intangible assets in future periods. See Note 13 “Goodwill and Intangible Assets” to the Consolidated Financial Statements in Item 8.
If economic conditions deteriorate, or operating performance of our reporting units do not meet expectations such that we revise our long-term forecasts, we may recognize impairments of goodwill and other intangible assets in future periods. See Note 12 “Goodwill and Intangible Assets” to the Consolidated Financial Statements in Item 8.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for loss from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, business acquisition and integration expense, litigation reserve, loss on assets held for sale, debt modification costs, and gain on sale of assets.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for (income) loss from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, business integration expense, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs.
In the event of unexpected market conditions or negative economic changes that could negatively affect Adtalem’s earnings and/or operating cash flow, Adtalem maintains a $400.0 million revolving credit facility with availability of $242.1 million as of June 30, 2024.
In the event of unexpected market conditions or negative economic changes that could negatively affect Adtalem’s earnings and/or operating cash flow, Adtalem maintained a $400.0 million revolving credit facility with availability of $400.0 million as of June 30, 2025.
The following are non-GAAP financial measures used in this Annual Report on Form 10-K: Adjusted net income (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for restructuring expense, business acquisition and integration expense, amortization of acquired intangible assets, gain on sale of assets, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, loss on assets held for sale, debt modification costs, tax benefit due to change in valuation allowance, tax benefit due to change in unrecognized tax benefits, and loss from discontinued operations.
The following are non-GAAP financial measures used in this Annual Report on Form 10-K: Adjusted net income (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, strategic advisory costs, tax benefit due to change in unrecognized tax benefits, and (income) loss from discontinued operations.
This cost increase was primarily driven by an increase in labor and other costs to support increased enrollment, and an increase in provision for bad debts at Chamberlain and Walden. As a percentage of revenue, cost of educational services was 44.1% in fiscal year 2024 compared to 44.7% in the prior year.
This cost increase was primarily driven by an increase in labor and other costs to support increased enrollment and the provision for bad debts. As a percentage of revenue, cost of educational services was 43.1% in fiscal year 2025 compared to 44.1% in the prior year.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Adtalem’s operating income adjusted for restructuring expense, business acquisition and integration expense, amortization of acquired intangible assets, litigation reserve, loss on assets held for sale, debt modification costs, and gain on sale of assets.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Adtalem’s operating income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs.
Each of these factors and assumptions can significantly affect the value of the intangible asset. Based on these quantitative assessments, it was determined that the fair values of these indefinite-lived intangible assets in the AUC reporting unit exceeded their carrying values by at least 23% and therefore no impairment was identified.
Each of these factors and assumptions can significantly affect the value of the intangible asset. Based on these quantitative assessments, it was determined that the fair values of these indefinite-lived intangible assets in the RUSM reporting unit exceeded their carrying values by over 2,000% and therefore no impairment was identified.
It should also be read in conjunction with the Cautionary Disclosure Regarding Forward-Looking Statements (see the Introduction section preceding Part I), the Risk Factors (see Item 1A. “Risk Factors”), and the Financial Aid and Legislative and Regulatory Requirements (see Item 1. “Business”) disclosures set forth in this report.
It should also be read in conjunction with the Cautionary Disclosure Regarding Forward-Looking Statements (see the Introduction section preceding Part I), the Risk Factors (see Item 1A. “Risk Factors”), and the Financial Aid and Legislative and Regulatory Requirements (see Item 1. “Business”) disclosures set forth in this report. Adtalem reports on a fiscal year period ending on June 30.
The adjusted operating income increase in fiscal year 2024 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, incentive compensation expense, marketing expense, and provision for bad debts.
The adjusted operating income increase in fiscal year 2025 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, and stock-based compensation.
The adjusted operating income increase in fiscal year 2024 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, incentive compensation expense, marketing expense, and provision for bad debts.
The adjusted operating income increase in fiscal year 2025 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, stock-based compensation, marketing expense, investments to support growth initiatives, and the provision for bad debts.
Adtalem’s consolidated cash and cash equivalents balance of $219.3 million and $272.2 million as of June 30, 2024 and 2023, respectively, included cash and cash equivalents held at Adtalem’s international operations of $4.6 million and $7.2 million as of June 30, 2024 and 2023, respectively, which is available to Adtalem for general corpora te purposes.
Adtalem’s consolidated cash and cash equivalents balance of $199.6 million and $219.3 million as of June 30, 2025 and 2024, respectively, included cash and cash equivalents held at Adtalem’s international operations of $22.9 million and $4.6 million as of June 30, 2025 and 2024, respectively, which is available to Adtalem for general corpora te purposes.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Adtalem’s diluted earnings per share adjusted for restructuring expense, business acquisition and integration expense, amortization of acquired intangible assets, gain on sale of assets, write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, loss on assets held for sale, debt modification costs, tax benefit due to change in valuation allowance, tax benefit due to change in unrecognized tax benefits, and loss from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Adtalem’s diluted earnings per share adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, strategic advisory costs, tax benefit due to change in unrecognized tax benefits, and (income) loss from discontinued operations.
The with and without method of the income approach and the relief from royalty model used in the determination of the fair values of our AUC Title IV eligibility and trade name intangible assets, respectively, during fiscal year 2024 reflected our most recent revenue projections, a discount rate of 12.5%, a royalty rate of 5.5%, and a terminal growth rate of 3.0%.
The relief-from-royalty method of the income approach and the with-and-without method of the income approach used in the determination of the fair values of our RUSM trade name and RUSM Title IV eligibility and accreditation indefinite-lived intangible assets, respectively, during fiscal year 2025 reflected our most recent revenue projections, a discount rate of 13.8%, a royalty rate of 5.5%, and a terminal growth rate of 3.0%.
This cost increase was primarily driven by an increase in incentive compensation expense, marketing expense, and investments to support growth initiatives. As a percentage of revenue, student services and administrative expense was 39.9% in fiscal year 2024 compared to 40.4% in the prior year.
This cost increase was primarily driven by an increase in marketing expense, investments to support growth initiatives, and stock-based compensation. As a percentage of revenue, student services and administrative expense was 37.6% in fiscal year 2025 compared to 39.9% in the prior year.
Our effective tax rate from continuing operations was 16.0% and 9.2% in fiscal year 2024 and 2023, respectively. In fiscal year 2024, our effective tax rate increase was primarily due to an increase in the percentage of earnings operations in higher taxed jurisdictions and a limitation of tax benefits on certain executive compensation.
Our effective tax rate from continuing operations was 22.1% and 16.0% in fiscal year 2025 and 2024, respectively. The effective tax rate for fiscal year 2025 increased compared to the prior year primarily due to an increase in the percentage of earnings from operations in higher taxed jurisdictions and a limitation of tax benefits on certain executive compensation.
“Financial Statements and Supplementary Data” for additional information on our credit losses. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
See Note 9 “Accounts and Financing Receivables” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information on our credit losses. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
As of June 30, 2024, total student enrollment at Walden increased 11.3% compared to June 30, 2023. ● For fiscal year 2024, average total student enrollment at the medical and veterinary schools decreased 5.1% compared to the prior year .
As of June 30, 2025, total student enrollment at Walden increased 15.0% compared to June 30, 2024. ● For fiscal year 2025, average total student enrollment at the medical and veterinary schools increased 0.5% compared to the prior year .
As of June 30, 2024, $211.6 million of authorized share repurchases were remaining under the fourteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. See Note 16 “Share Repurchases” to the Consolidated Financial Statements in Item 8.
As of June 30, 2025, $150.0 million of authorized share repurchases remained under the fifteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. See Note 14 “Share Repurchases” to the Consolidated Financial Statements in Item 8.
This increase was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, investments to support growth initiatives, incentive compensation expense, provision for bad debts, and provision for income taxes. 37 Table of Contents ● Diluted adjusted earnings per share increased 19.0%, or $0.80, to $5.01 in fiscal year 2024 compared to the prior year driven by the increase in adjusted net income and lower diluted shares due to share repurchases. ● For fiscal year 2024, average total student enrollment at Chamberlain increased 6.9% compared to the prior year .
This increase was primarily driven by an increase in revenue and a decrease in interest expense, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, stock-based compensation, and the provision for income taxes. ● Diluted adjusted earnings per share increased 33.1%, or $1.66, to $6.67 in fiscal year 2025 compared to the prior year driven by the increase in adjusted net income and lower diluted shares due to share repurchases. 36 Table of Contents ● For fiscal year 2025, average total student enrollment at Chamberlain increased 9.3% compared to the prior year .
Significant assumptions used in the determination of reporting unit fair value measurements generally include forecasted cash flows, discount rates, terminal growth rates, and earnings multiples.
Determining the fair value of a reporting unit or an intangible asset involves the use of significant estimates and assumptions. Significant assumptions used in the determination of reporting unit fair value measurements generally include forecasted cash flows, discount rates, terminal growth rates, and earnings multiples.
A description of special items in our non-GAAP financial measures described above are as follows: ● Restructuring expense primarily related to real estate consolidations at Walden, Medical and Veterinary, and Adtalem’s home office.
A description of special items in our non-GAAP financial measures described above are as follows: ● Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Adtalem’s home office.
For the May 2024 semester, total student enrollment at the medical and veterinary schools decreased 2.9% compared to the same semester last year. ● On January 26, 2024, we made a prepayment of $50.0 million on our Term Loan B debt. ● Adtalem repurchased a total of 5,446,113 shares of its common stock under its share repurchase programs at an average cost of $47.96 per share during fiscal year 2024.
For the May 2025 semester, total student enrollment at the medical and veterinary schools increased 1.0% compared to the same semester last year. ● On January 17, 2025, we made a prepayment of $100.0 million on our Term Loan B debt. ● Adtalem repurchased a total of 2,317,937 shares of its common stock under its share repurchase programs at an average cost of $91.21 per share during fiscal year 2025.
Critical accounting estimates discussed below are those that we believe involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial 47 Table of Contents condition or results of operations. Although management believes its assumptions and estimates are reasonable, actual results could differ from those estimates.
Critical accounting estimates discussed below are those that we believe involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.
This expense category also includes the costs of facilities, adjunct faculty, supplies, housing, bookstore, other educational materials, student education-related support activities, and the provision for bad debts.
Cost of Educational Services The cost of educational services expense category includes expenses related to the cost of faculty and staff who support educational operations, facilities, adjunct faculty, supplies, housing, bookstore, other educational materials, student education-related support activities, and the provision for bad debts.
The operating income increase in fiscal year 2024 was primarily driven by an increase in revenue and decreases in restructuring expense, business acquisition and integration expense, and amortization of acquired intangible assets, partially offset by increases in litigation reserves, labor and other costs to support increased enrollment, incentive compensation expense, marketing expense, and provision for bad debts, and the gain on sale of assets in fiscal year 2023.
The operating income increase in fiscal year 2025 was primarily driven by an increase in revenue and decreases in business integration expense, amortization of acquired intangible assets, and litigation reserves, partially offset by increases in asset impairments, strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, and stock-based compensation.
Walden revenue increased 11.5%, or $61.6 million, to $595.3 million in fiscal year 2024 compared to the prior year driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student.
Walden revenue increased 16.5%, or $98.1 million, to $693.4 million in fiscal year 2025 compared to the prior year driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student.
This measure is applied on a consolidated and segment basis, depending on the context of the discussion. Provision for income taxes, interest expense, and other income, net is not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with operating income.
Provision for income taxes, interest expense, and other income, net is not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.
The decrease in amortization of acquired intangible assets is driven by the decrease in amortization relating to the Walden student relationships intangible asset.
The decrease in amortization of acquired intangible assets is driven by the decrease in amortization relating to the Walden student relationships intangible asset, which was fully amortized as of June 30, 2024.
For the May 2024 session, total student enrollment at Chamberlain increased 10.4% compared to the same session last year. ● For fiscal year 2024, average total student enrollment at Walden increased 6.9% compared to the prior year .
For the May 2025 session, total student enrollment at Chamberlain increased 5.8% compared to the same session last year. ● For fiscal year 2025, average total student enrollment at Walden increased 13.5% compared to the prior year .
On January 16, 2024, Adtalem completed its thirteenth share repurchase program. On January 19, 2024, we announced that the Board of Directors authorized Adtalem’s fourteenth share repurchase program, which allows repurchase of up to $300.0 million of its common stock through January 16, 2027.
On May 5, 2025, Adtalem completed its fourteenth share repurchase program. On May 6, 2025, we announced that the Board of Directors authorized Adtalem’s fifteenth share repurchase program, which allows Adtalem to repurchase up to $150.0 million of its common stock through May 6, 2028.
The adjusted operating income increase in fiscal year 2024 was primarily driven by the increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, incentive compensation expense, and provision for bad debts.
The adjusted operating income increase in fiscal year 2025 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, stock-based compensation, marketing expense, and investments to support growth initiatives.
If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group.
If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group. Intangible assets with finite lives are amortized over their expected economic lives, which is five years.
Walden Walden Student Enrollment: Fiscal Year 2024 September 30, December 31, March 31, June 30, Period 2023 2023 2024 2024 Total students 40,975 40,971 42,751 41,845 % change from prior year 0.5 % 7.9 % 8.4 % 11.3 % Fiscal Year 2023 September 30, December 31, March 31, June 30, Period 2022 2022 2023 2023 Total students 40,772 37,956 39,427 37,582 % change from prior year (9.2) % (7.8) % (7.9) % (4.8) % Walden total student enrollment represents those students attending instructional sessions as of the dates identified above.
The average increase across all these programs was approximately 4.3% from the prior year. 38 Table of Contents Walden Walden Student Enrollment: Fiscal Year 2025 September 30, December 31, March 31, June 30, Period 2024 2024 2025 2025 Total students 45,979 46,399 48,526 48,116 % change from prior year 12.2 % 13.2 % 13.5 % 15.0 % Fiscal Year 2024 September 30, December 31, March 31, June 30, Period 2023 2023 2024 2024 Total students 40,975 40,971 42,751 41,845 % change from prior year 0.5 % 7.9 % 8.4 % 11.3 % Walden total student enrollment represents those students attending instructional sessions as of the dates identified above.
Results of Operations Revenue The following table presents revenue by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2024 Chamberlain Walden Medical and Veterinary Consolidated Fiscal year 2023 $ 571,034 $ 533,725 $ 346,067 $ 1,450,826 Growth 62,488 61,607 9,731 133,826 Fiscal year 2024 $ 633,522 $ 595,332 $ 355,798 $ 1,584,652 % change from prior year 10.9 % 11.5 % 2.8 % 9.2 % Chamberlain Chamberlain Student Enrollment: Fiscal Year 2024 Session July 2023 Sept. 2023 Nov. 2023 Jan. 2024 Mar. 2024 May 2024 Total students 32,175 34,889 35,592 37,196 37,985 36,750 % change from prior year 2.6 % 5.2 % 6.6 % 7.0 % 9.0 % 10.4 % Fiscal Year 2023 Session July 2022 Sept. 2022 Nov. 2022 Jan. 2023 Mar. 2023 May 2023 Total students 31,371 33,153 33,390 34,760 34,847 33,284 % change from prior year (4.1) % (4.0) % (0.8) % 1.8 % 2.0 % 1.2 % Chamberlain revenue increased 10.9%, or $62.5 million, to $633.5 million in fiscal year 2024 compared to the prior year, driven by an increase in enrollment and higher tuition rates.
Results of Operations Revenue The following table presents revenue by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2025 Chamberlain Walden Medical and Veterinary Consolidated Fiscal year 2024 $ 633,522 $ 595,332 $ 355,798 $ 1,584,652 Growth 92,252 98,098 13,288 203,638 Fiscal year 2025 $ 725,774 $ 693,430 $ 369,086 $ 1,788,290 % change from prior year 14.6 % 16.5 % 3.7 % 12.9 % Chamberlain Chamberlain Student Enrollment: Fiscal Year 2025 Session July 2024 Sept. 2024 Nov. 2024 Jan. 2025 Mar. 2025 May 2025 Total students 36,061 38,987 39,691 40,445 40,564 38,891 % change from prior year 12.1 % 11.7 % 11.5 % 8.7 % 6.8 % 5.8 % Fiscal Year 2024 Session July 2023 Sept. 2023 Nov. 2023 Jan. 2024 Mar. 2024 May 2024 Total students 32,175 34,889 35,592 37,196 37,985 36,750 % change from prior year 2.6 % 5.2 % 6.6 % 7.0 % 9.0 % 10.4 % Chamberlain revenue increased 14.6%, or $92.3 million, to $725.8 million in fiscal year 2025 compared to the prior year, driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student.
Excluding amortization of acquired intangible assets, litigation reserve, loss on assets held for 41 Table of Contents sale, and debt modification costs, student services and administrative expense increased 10.7%, or $62.6 million, in fiscal year 2024 compared to the prior year.
After excluding amortization of acquired intangible assets, litigation reserves, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs, student services and administrative expense increased 11.0%, or $69.4 million, in fiscal year 2025 compared to the prior year.
This increase was primarily driven by an increase in revenue along with decreases in amortization of acquired intangible assets, restructuring expense, business acquisition and integration expense, and write-off of debt discount and issuance costs in fiscal year 2024, partially offset by increases in labor and other costs to support increased enrollment, investments to support growth initiatives, incentive compensation expense, provision for bad debts, and the provision for income taxes, and a decrease in gain on sale of assets. ● Diluted earnings per share increased 65.4%, or $1.34, to $3.39 in fiscal year 2024 compared to the prior year driven by the increase in net income and lower diluted shares due to share repurchases. ● Adjusted net income increased 5.0%, or $9.6 million, to $201.8 million in fiscal year 2024 compared to the prior year.
This increase was primarily driven by an increase in revenue along with decreases in interest expense, business integration expense, amortization of acquired intangible assets, and litigation reserves, partially offset by increases in asset impairments, strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, stock-based compensation, and the provision for income taxes. ● Diluted earnings per share increased 82.3%, or $2.79, to $6.18 in fiscal year 2025 compared to the prior year driven by the increase in net income and lower diluted shares due to share repurchases. ● Adjusted net income increased 26.7%, or $53.8 million, to $255.6 million in fiscal year 2025 compared to the prior year.
In addition, we sublease certain space to third parties, which partially offsets the lease obligations at these facilities. See Note 12 “Leases” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information on our lease agreements.
Operating Lease Obligations – We have operating lease obligations for the minimum payments required under various lease agreements which are recorded on the Consolidated Balance Sheets. In addition, we sublease certain space to third parties, which partially offsets the lease obligations at these facilities. See Note 11 “Leases” to the Consolidated Financial Statements in Item 8.
In addition, we continue to incur costs associated with ongoing litigation and settlements related to the DeVry University and Carrington College divestitures, which were completed during fiscal year 2019, and are classified as expense within discontinued operations. Loss from discontinued operations in fiscal year 2024 was $0.9 million.
We recorded income within discontinued operations related to the DeVry University earn-out of $7.0 million and $5.5 million in fiscal year 2025 and 2024, respectively. In addition, we continue to incur costs associated with ongoing litigation and settlements related to divestitures, which are classified as expenses within discontinued operations.
Chamberlain Chamberlain operating income increased 2.3%, or $3.1 million, to $137.8 million in fiscal year 2024 compared to the prior year. Segment adjusted operating income increased 1.7%, or $2.3 million, to $137.8 million in fiscal year 2024 compared to the prior year.
Chamberlain Segment adjusted operating income increased 11.3%, or $15.6 million, to $153.4 million in fiscal year 2025 compared to the prior year.
The estimate of our credit losses involves a significant level of uncertainty as it requires significant judgment to estimate the amount we will collect in the future on our accounts and financing receivable balances. See Note 10 “Accounts and Financing Receivables” to the Consolidated Financial Statements in Item 8.
In evaluating the collectability of our accounts and financing receivable balances, we utilize historical events, current conditions, and reasonable and supportable forecasts about the future. The estimate of our credit losses involves a significant level of uncertainty as it requires significant judgment to estimate the amount we will collect in the future on our accounts and financing receivable balances.
Medical and Veterinary Medical and Veterinary operating income increased 19.1%, or $11.4 million, to $71.1 million in fiscal year 2024 compared to the prior year. Segment adjusted operating income increased 6.2%, or $4.2 million, to $71.5 million in fiscal year 2024 compared to the prior year.
Medical and Veterinary Segment adjusted operating income decreased 3.2%, or $2.3 million, to $69.3 million in fiscal year 2025 compared to the prior year.
See Note 14 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information on the Notes and our Credit Agreement. Many states require private-sector postsecondary education institutions to post surety bonds for licensure.
As of June 30, 2025, Adtalem had $179.0 million of letters of credit outstanding in favor of ED. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information. Many states require private-sector postsecondary education institutions to post surety bonds for licensure.
Net income reconciliation to adjusted net income (in thousands): Year Ended June 30, 2024 2023 Net income (GAAP) $ 136,777 $ 93,358 Restructuring expense 1,870 18,817 Business acquisition and integration expense 34,215 42,661 Amortization of acquired intangible assets 35,644 61,239 Gain on sale of assets — (13,317) Write-off of debt discount and issuance costs, gain on extinguishment of debt, litigation reserve, investment impairment, loss on assets held for sale, and debt modification costs 21,108 19,226 Tax benefit due to change in valuation allowance — (6,184) Tax benefit due to change in unrecognized tax benefits (5,657) — Income tax impact on non-GAAP adjustments (1) (23,104) (31,997) Loss from discontinued operations 936 8,394 Adjusted net income (non-GAAP) $ 201,789 $ 192,197 (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.
The operating income reconciliation is included in the results of operations section within this MD&A. 48 Table of Contents Net income reconciliation to adjusted net income (in thousands): Year Ended June 30, 2025 2024 Net income (GAAP) $ 237,065 $ 136,777 Restructuring expense 3,314 1,870 Business integration expense — 34,215 Amortization of acquired intangible assets 11,220 35,644 Write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs 3,832 21,108 Strategic advisory costs 12,000 — Tax benefit due to change in unrecognized tax benefits — (5,657) Income tax impact on non-GAAP adjustments (1) (7,423) (23,104) (Income) loss from discontinued operations (4,388) 936 Adjusted net income (non-GAAP) $ 255,620 $ 201,789 (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.
These tuition rates, event charges, and fees do not include the cost of books or personal technology, supplies, transportation, or living expenses. 39 Table of Contents Medical and Veterinary Medical and Veterinary Student Enrollment: Fiscal Year 2024 Semester Sept. 2023 Jan. 2024 May 2024 Total students 5,209 5,073 4,726 % change from prior year (7.5) % (4.5) % (2.9) % Fiscal Year 2023 Semester Sept. 2022 Jan. 2023 May 2023 Total students 5,634 5,312 4,869 % change from prior year 3.4 % 1.6 % (8.2) % Medical and Veterinary revenue increased 2.8%, or $9.7 million, to $355.8 million in fiscal year 2024 compared to the prior year, driven by tuition rate increases at all three institutions in this segment, partially offset by decreased enrollment at all three institutions.
Medical and Veterinary Medical and Veterinary Student Enrollment: Fiscal Year 2025 Semester Sept. 2024 Jan. 2025 May 2025 Total students 5,174 5,133 4,773 % change from prior year (0.7) % 1.2 % 1.0 % Fiscal Year 2024 Semester Sept. 2023 Jan. 2024 May 2024 Total students 5,209 5,073 4,726 % change from prior year (7.5) % (4.5) % (2.9) % Medical and Veterinary revenue increased 3.7%, or $13.3 million, to $369.1 million in fiscal year 2025 compared to the prior year, driven by tuition rate increases at all three institutions in this segment.
The following table presents cost of educational services by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2024 Chamberlain Walden Medical and Veterinary Consolidated Fiscal year 2023 $ 248,727 $ 199,625 $ 200,134 $ 648,486 Cost increase 28,488 21,485 89 50,062 Fiscal year 2024 $ 277,215 $ 221,110 $ 200,223 $ 698,548 % change from prior year 11.5 % 10.8 % 0.0 % 7.7 % Cost of educational services increased 7.7%, or $50.1 million, to $698.5 million in fiscal year 2024 compared to the prior year.
The following table presents cost of educational services by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2025 Chamberlain Walden Medical and Veterinary Consolidated Fiscal year 2024 $ 277,215 $ 221,110 $ 200,223 $ 698,548 Cost increase 44,554 18,974 9,354 72,882 Fiscal year 2025 $ 321,769 $ 240,084 $ 209,577 $ 771,430 % change from prior year 16.1 % 8.6 % 4.7 % 10.4 % Cost of educational services increased 10.4%, or $72.9 million, to $771.4 million in fiscal year 2025 compared to the prior year.
The following table presents student services and administrative expense by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2024 Chamberlain Walden Medical and Veterinary Home Office Consolidated Fiscal year 2023 $ 186,805 $ 294,974 $ 78,598 $ 25,632 $ 586,009 Cost increase 31,702 19,940 5,470 5,444 62,556 Amortization of acquired intangible assets decrease — (25,595) — — (25,595) Litigation reserve increase — 8,500 — — 8,500 Loss on assets held for sale increase — — — 647 647 Debt modification costs increase — — — 848 848 Fiscal year 2024 $ 218,507 $ 297,819 $ 84,068 $ 32,571 $ 632,965 Fiscal year 2024 % change: Cost increase 17.0 % 6.8 % 7.0 % NM 10.7 % Amortization of acquired intangible assets decrease — (8.7) % — NM (4.4) % Litigation reserve increase — 2.9 % — NM 1.5 % Loss on assets held for sale increase — — — NM 0.1 % Debt modification costs increase — — — NM 0.1 % Fiscal year 2024 % change 17.0 % 1.0 % 7.0 % NM 8.0 % Student services and administrative expense increased 8.0%, or $47.0 million, to $633.0 million in fiscal year 2024 compared to the prior year.
The following table presents student services and administrative expense by segment detailing the changes from the prior year (in thousands): Year Ended June 30, 2025 Chamberlain Walden Medical and Veterinary Home Office Consolidated Fiscal year 2024 $ 218,507 $ 297,819 $ 84,068 $ 32,571 $ 632,965 Cost increase 32,131 26,090 6,189 4,954 69,364 Amortization of acquired intangible assets decrease — (24,424) — — (24,424) Litigation reserve decrease — (24,050) — — (24,050) Asset impairments increase — — — 6,442 6,442 Strategic advisory costs increase — — — 12,000 12,000 Loss on assets held for sale decrease — — — (157) (157) Debt modification costs decrease — — — (136) (136) Fiscal year 2025 $ 250,638 $ 275,435 $ 90,257 $ 55,674 $ 672,004 Fiscal year 2025 % change: Cost increase 14.7 % 8.8 % 7.4 % NM 11.0 % Amortization of acquired intangible assets decrease — (8.2) % — NM (3.9) % Litigation reserve decrease — (8.1) % — NM (3.8) % Asset impairments increase — — — NM 1.0 % Strategic advisory costs increase — — — NM 1.9 % Loss on assets held for sale decrease — — — NM (0.0) % Debt modification costs decrease — — — NM (0.0) % Fiscal year 2025 % change 14.7 % (7.5) % 7.4 % NM 6.2 % 40 Table of Contents Student services and administrative expense increased 6.2%, or $39.0 million, to $672.0 million in fiscal year 2025 compared to the prior year.
In the U.S., Adtalem has posted $44.3 million of surety bonds as of June 30, 2024 with regulatory authorities on behalf of Chamberlain, Walden, AUC, RUSM, and RUSVM. Operating Lease Obligations – We have operating lease obligations for the minimum payments required under various lease agreements which are recorded on the Consolidated Balance Sheets.
In the U.S., Adtalem has posted $67.3 million of surety bonds as of June 30, 2025 with regulatory authorities on behalf of Chamberlain, Walden, AUC, RUSM, and RUSVM.
Based on this quantitative assessment, it was determined that the fair value of the AUC reporting unit exceeded its carrying value by approximately 20% and therefore no goodwill impairment was identified. Significant judgments and assumptions were used in determining the fair value of intangible assets.
Each of these inputs can significantly affect the fair values of our reporting units. Based on this quantitative assessment, it was determined that the fair value of the RUSM reporting unit exceeded its carrying value by approximately 165% and therefore no goodwill impairment was identified.
Fiscal Year 2024 Highlights Financial and operational highlights for fiscal year 2024 include: ● Adtalem revenue increased 9.2%, or $133.8 million, to $1,584.7 million in fiscal year 2024 compared to the prior year driven by increased revenue across all of our segments. ● Net income increased 46.5%, or $43.4 million, to $136.8 million in fiscal year 2024 compared to the prior year.
“Financial Statements and Supplementary Data.” Fiscal Year 2025 Highlights Financial and operational highlights for fiscal year 2025 include: ● Adtalem revenue increased 12.9%, or $203.6 million, to $1,788.3 million in fiscal year 2025 compared to the prior year driven by increased revenue across all of our segments. ● Net income increased 73.3%, or $100.3 million, to $237.1 million in fiscal year 2025 compared to the prior year.
See Note 14 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information on the Notes and our Credit Agreement.
As a result of previous Term Loan B prepayments, we are no longer required to make quarterly principal installment payments on the Term Loan B. See Note 13 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information on the Notes and our Credit Agreement.
Other Income, Net Other income, net was income of $10.5 million and income of $7.0 million in fiscal year 2024 and 2023, respectively. The other income, net increase in fiscal year 2024 was primarily driven by $5.0 million of expense in fiscal year 2023 for an impairment of an equity investment.
Other Income, Net Other income, net was income of $9.3 million and income of $10.5 million in fiscal year 2025 and 2024, respectively. This decrease was primarily driven by decreases in interest income and investment income.
“Financial Statements and Supplementary Data.” Segments We present three reportable segments as follows: Chamberlain – Offers degree and certificate programs in the nursing and health professions postsecondary education industry. Walden – Offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
Walden’s performance turnaround in enrollment in fiscal year 2024 has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning® competency-based programs.
Walden’s improved enrollment has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning® competency-based programs. Tuition Rates: Tuition rates for Walden programs, including general education are charged on a per credit hour basis that varies based on the nature of the program.
The discounted cash flow models used to determine the fair value of our AUC reporting unit during fiscal year 2024 reflected our most recent cash 48 Table of Contents flow projections, a discount rate of 12.5%, and a terminal growth rate of 3.0%. Each of these inputs can significantly affect the fair values of our reporting units.
The discounted cash flow method used to determine the fair value of our RUSM reporting unit during fiscal year 2025 reflected our most recent cash flow projections, a discount rate of 13.8%, and a terminal growth rate of 3.0%. The significant assumptions used in the market comparable method include 46 Table of Contents earnings multiples for comparable companies.
The adjusted operating income increase in fiscal year 2024 was primarily driven by an increase in revenue and a decrease in provision for bad debts. Interest Expense Interest expense was $63.7 million and $63.1 million in fiscal year 2024 and 2023, respectively.
The adjusted operating income decrease in fiscal year 2025 was primarily driven by increases in investments to support initiatives to drive future growth, investments in academic support, and stock-based compensation, partially offset by an increase in revenue. Interest Expense Interest expense was $52.3 million and $63.7 million in fiscal year 2025 and 2024, respectively.
The capital expenditures in fiscal year 2024 primarily consisted of spending for information technology investments and Chamberlain’s campus development. For fiscal year 2025, we expect capital spending on information technology, new campus development at Chamberlain, and facility improvements at the medical and veterinary schools. Management anticipates fiscal year 2025 capital spending to be in the $55 to $75 million range.
The capital expenditures in fiscal year 2025 primarily consisted of spending for information technology investments and Chamberlain’s campus development.
“Financial Statements and Supplementary Data.” 42 Table of Contents Operating Income The following table presents a reconciliation of operating income (GAAP) to adjusted operating income (non-GAAP) by segment (in thousands): Year Ended June 30, Increase/(Decrease) 2024 2023 $ % Chamberlain: Operating income (GAAP) $ 137,800 $ 134,685 $ 3,115 2.3 % Restructuring expense — 818 (818) Adjusted operating income (non-GAAP) $ 137,800 $ 135,503 $ 2,297 1.7 % Operating margin (GAAP) 21.8 % 23.6 % Operating margin (non-GAAP) 21.8 % 23.7 % Walden: Operating income (GAAP) $ 77,179 $ 35,880 $ 41,299 115.1 % Restructuring expense (776) 3,245 (4,021) Amortization of acquired intangible assets 35,644 61,239 (25,595) Litigation reserve 18,500 10,000 8,500 Adjusted operating income (non-GAAP) $ 130,547 $ 110,364 $ 20,183 18.3 % Operating margin (GAAP) 13.0 % 6.7 % Operating margin (non-GAAP) 21.9 % 20.7 % Medical and Veterinary: Operating income (GAAP) $ 71,065 $ 59,649 $ 11,416 19.1 % Restructuring expense 442 7,687 (7,245) Adjusted operating income (non-GAAP) $ 71,507 $ 67,336 $ 4,171 6.2 % Operating margin (GAAP) 20.0 % 17.2 % Operating margin (non-GAAP) 20.1 % 19.5 % Home Office: Operating loss (GAAP) $ (68,990) $ (62,044) $ (6,946) (11.2) % Restructuring expense 2,204 7,067 (4,863) Business acquisition and integration expense 34,215 42,661 (8,446) Loss on assets held for sale 647 — 647 Debt modification costs 848 — 848 Gain on sale of assets — (13,317) 13,317 Adjusted operating loss (non-GAAP) $ (31,076) $ (25,633) $ (5,443) (21.2) % Adtalem Global Education: Operating income (GAAP) $ 217,054 $ 168,170 $ 48,884 29.1 % Restructuring expense 1,870 18,817 (16,947) Business acquisition and integration expense 34,215 42,661 (8,446) Amortization of acquired intangible assets 35,644 61,239 (25,595) Litigation reserve 18,500 10,000 8,500 Loss on assets held for sale 647 — 647 Debt modification costs 848 — 848 Gain on sale of assets — (13,317) 13,317 Adjusted operating income (non-GAAP) $ 308,778 $ 287,570 $ 21,208 7.4 % Operating margin (GAAP) 13.7 % 11.6 % Operating margin (non-GAAP) 19.5 % 19.8 % Consolidated operating income increased 29.1%, or $48.9 million, to $217.1 million in fiscal year 2024 compared to the prior year.
In the prior year, we incurred certain costs relating to transformation initiatives to accelerate growth and organizational agility that were included in business integration expense in the Consolidated Statements of Income. 41 Table of Contents Operating Income The following table presents a reconciliation of operating income to adjusted operating income by segment (in thousands): Year Ended June 30, Increase/(Decrease) 2025 2024 $ % Chamberlain: Operating income $ 151,455 $ 137,800 $ 13,655 9.9 % Restructuring expense 1,912 — 1,912 Adjusted operating income $ 153,367 $ 137,800 $ 15,567 11.3 % Operating margin 20.9 % 21.8 % Adjusted operating margin 21.1 % 21.8 % Walden: Operating income $ 177,911 $ 77,179 $ 100,732 130.5 % Restructuring expense — (776) 776 Amortization of acquired intangible assets 11,220 35,644 (24,424) Litigation reserve (5,550) 18,500 (24,050) Adjusted operating income $ 183,581 $ 130,547 $ 53,034 40.6 % Operating margin 25.7 % 13.0 % Adjusted operating margin 26.5 % 21.9 % Medical and Veterinary: Operating income $ 68,798 $ 71,065 $ (2,267) (3.2) % Restructuring expense 454 442 12 Adjusted operating income $ 69,252 $ 71,507 $ (2,255) (3.2) % Operating margin 18.6 % 20.0 % Adjusted operating margin 18.8 % 20.1 % Home Office: Operating loss $ (56,622) $ (68,990) $ 12,368 17.9 % Restructuring expense 948 2,204 (1,256) Business integration expense — 34,215 (34,215) Asset impairments 6,442 — 6,442 Strategic advisory costs 12,000 — 12,000 Loss on assets held for sale 490 647 (157) Debt modification costs 712 848 (136) Adjusted operating loss $ (36,030) $ (31,076) $ (4,954) (15.9) % Adtalem Global Education: Operating income (GAAP) $ 341,542 $ 217,054 $ 124,488 57.4 % Restructuring expense 3,314 1,870 1,444 Business integration expense — 34,215 (34,215) Amortization of acquired intangible assets 11,220 35,644 (24,424) Litigation reserve (5,550) 18,500 (24,050) Asset impairments 6,442 — 6,442 Strategic advisory costs 12,000 — 12,000 Loss on assets held for sale 490 647 (157) Debt modification costs 712 848 (136) Adjusted operating income (non-GAAP) $ 370,170 $ 308,778 $ 61,392 19.9 % Operating margin (GAAP) 19.1 % 13.7 % Adjusted operating margin (non-GAAP) 20.7 % 19.5 % Consolidated operating income increased 57.4%, or $124.5 million, to $341.5 million in fiscal year 2025 compared to the prior year.
This increase was primarily driven by the increase in letter of credit fees (as discussed in Note 14 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data”), partially offset by lower write-offs on debt discount and issuance costs on Term Loan B in the current year compared to the prior year.
This decrease was primarily driven by lower interest expense on our Term Loan B due to decreased borrowings and a lower interest rate (as discussed in Note 13 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data”).
The decrease in the percentage was primarily the result of efficiencies in marketing spend and a decrease in amortization of acquired intangible assets. Restructuring Expense Restructuring expense was $1.9 million and $18.8 million in fiscal year 2024 and 2023, respectively.
The decrease in the percentage was primarily the result of revenue growth accompanied by decreases in amortization of acquired intangible assets and litigation reserves, partially offset by increases in asset impairments and strategic advisory costs. Restructuring Expense Restructuring expense was $3.3 million and $1.9 million in fiscal year 2025 and 2024, respectively.
Credit Losses The allowance for credit losses represents an estimate of the lifetime expected credit losses inherent in our accounts and financing receivable balances as of each balance sheet date. In evaluating the collectability of our accounts and financing receivable balances, we utilize historical events, current conditions, and reasonable and supportable forecasts about the future.
Although management believes its assumptions and estimates are reasonable, actual results could differ from those estimates. 45 Table of Contents Credit Losses The allowance for credit losses represents an estimate of the lifetime expected credit losses inherent in our accounts and financing receivable balances as of each balance sheet date.
Walden Walden operating income increased 115.1%, or $41.3 million, to $77.2 million in fiscal year 2024 compared to the prior year. Segment adjusted operating income increased 18.3%, or $20.2 million, to $130.5 million in fiscal year 2024 compared to the prior year.
Walden Segment adjusted operating income increased 40.6%, or $53.0 million, to $183.6 million in fiscal year 2025 compared to the prior year.
Material Cash Requirements Long-Term Debt – As of June 30, 2024, we have principal balances of $405.0 million of Notes and $253.3 million of Term Loan B, which requires interest payments. With the Term Loan B prepayments noted above, we are no longer required to make quarterly principal installment payments on the Term Loan B.
Material Cash Requirements Long-Term Debt – As of June 30, 2025, we have principal balances of $405.0 million of 5.50% Senior Secured Notes due 2028 (the “Notes”), which mature on March 1, 2028 and $153.3 million of Term Loan B under our Credit Facility, which matures on August 12, 2028 and requires interest payments.
“Financial Statements and Supplementary Data” for additional information on our share repurchase programs. On March 14, 2022, we entered into an ASR agreement to repurchase $150.0 million of common stock.
“Financial Statements and Supplementary Data” for additional information on our share repurchase programs.